A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFalpha Monoclonal Antibody, Administered Intravenously, in Subjects With Active Psoriatic Arthritis

Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFalpha Monoclonal Antibody, Administered Intravenously, in Subjects With Active Psoriatic Arthritis

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Aug 2017

At a glance

  • Drugs Golimumab (Primary)
  • Indications Psoriatic arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms GO - VIBRANT
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 13 Aug 2017 Results assessing safety and efficacy through week 24, published in the Arthritis and Rheumatology.
    • 17 Jun 2017 Primary endpoint of ACR20 response at wk14 has been met, according to results presented at the 18th Annual Congress of the European League Against Rheumatism.
    • 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top